Abeona Therapeutics (NASDAQ: ABEO) — Company Overview, News & Financial Data
Abeona Therapeutics develops gene and cell therapies for serious diseases, aiming to provide novel treatments for genetic disorders.
Abeona Therapeutics
Abeona Therapeutics (NASDAQ:ABEO) is dedicated to developing gene and cell therapies for people suffering from serious diseases. Specializing in the research and development of treatments for genetic disorders and other medical conditions, Abeona aims to transform cutting-edge scientific discoveries into novel therapies. Its pipeline includes projects targeting diseases such as Sanfilippo syndrome types A and B, among others, with a focus on delivering life-changing solutions to underserved patient populations. Abeona's objectives revolve around advancing these innovative therapies through clinical trials, striving for regulatory approvals, and ultimately improving patient outcomes by providing new treatment options. The company's efforts are guided by a commitment to scientific excellence and compassion for those they serve.
Snapshot
Operations
Products and/or services of Abeona Therapeutics
- EB-101 is a gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, addressing a significant unmet medical need by potentially providing durable wound healing.
- AAV-based gene therapies targeting rare genetic disorders, including treatments for Sanfilippo syndrome types A and B, offer hope in correcting genetic deficiencies with a single administration.
- Library of AAV-based capsids known as AIM™ provides a platform to develop targeted gene therapies for various diseases, leveraging next-generation capsid technology for enhanced delivery.
- Biostatistical consulting services support the development and commercialization of gene therapies, ensuring rigorous analysis and regulatory compliance.
- GMP manufacturing capabilities enable the production of high-quality gene therapy vectors, supporting both in-house projects and external partnerships.
- Collaboration with leading research institutions and biotech firms enhances the pipeline's diversity and accelerates the development of innovative gene therapy solutions.
Abeona Therapeutics executive team
- Vishwas SeshadriPresident, CEO & Director
- Joseph Walter VazzanoChief Financial Officer
- Brendan M. O'MalleyChief Legal Officer
- Brian KevanyChief Technical & Scientific Officer
- Gregory GinVice President of Investor Relations & Corporate Communications
- Gianine EspositoSenior VP & Chief People Officer
- Jon VossVP & Head of Quality
- Madhav VasanthavadaSVP, Chief Commercial Officer & Head of Business Development
- Carl DennySenior Vice President of Regulatory Affairs
- Megan CallanVice President & Head of Quality
Latest news about Abeona Therapeutics
Key financials
Reported results for Abeona Therapeutics, in USD.
- Market cap
- 260.8M
- Revenue (TTM)
- 25.5M
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.2
- Dividend yield
- —
- Profit margin
- -246.4%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 5.8M | -89.4M | 71.2M | |
| 0 | -64.2M | -63.7M | |
| 3.5M | -47.1M | -54.2M | |
| 1.4M | -50.9M | -39.7M |